AMAisha Mobashar

Aisha Mobashar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aisha Mobashar has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anti-arthritic and anti-inflammatory effects of BMZD-2CPE in a CFA and carrageenan-induced animal model

    by Samiullah Wazir, Farah Abid, Aisha Mobashar, Arham Shabbir, Muhammad Awais, Humaira Nadeem, Hafiz Aamir Ali Kharl, Esmael M. Alyami, Amir Bouallegue, Norah Hamdi, et al.

    The goal of the study was to evaluate the anti-inflammatory and immunomodulatory effects of benzimidazole derivative-2-((1H-benzo[d] imidazole-2-yl)thio)-1-(3-(3-chlorophenyl)-5-phenyl-1 H-pyrazol-1-yl) ethanone (BMZD-2CPE) in CFA-induced arthritic rat model. The doses of the BMZD-2CPE (benzimidazole derivative) used were 25, 50, and 75 mg/kg, respectively. Treatment with BMZD-2CPE and piroxicam was started on the 7th day of arthritic induction and continued for 20 days. All animals were sacrificed on the 27th day. A digital water plethysmometer was used to measure paw edema. An arthritic scoring index was used to determine the presence of arthritis. Biochemical parameters and blood analysis were determined. q-PCR was used to assess the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6. PGE2 levels were determined using ELISA. The anti-inflammatory properties of BMZD-2CPE were evaluated using an acute inflammatory carrageenan-induced paw edema model. BMZD-2CPE reduced paw edema and slowed the progression of arthritic disease. After receiving BMZD-2CPE treatment, all histopathological parameters were seen to be considerably decreased. mRNA expression levels of pro-inflammatory cytokines such as TNF-α and IL-6 were markedly decreased in treatment groups. BMZD-2CPE also downregulated PGE2 levels in treatment groups. All results were comparable to piroxicam. Hemoglobin (Hb) and red blood cell (RBC) levels were restored in the treated groups. Furthermore, the levels of white blood cells and platelets in the treated groups were significantly reduced. Creatinine, urea, alanine transaminase, and aspartate aminotransferase levels were found to be non-significantly different indicating safety of the compound. BMZD-2CPE in various doses (more potentially in higher dose) showed anti-inflammatory and immunomodulatory properties.

  • Open Access

    Potential antihyperlipidemic effects of myrcenol and curzerene in high-fat fed rats

    by Sana Tahir, Abdullah Abdo, Aisha Mobashar, Arham Shabbir, Komal Najam, Aisha Ibrahim, Khalid Hussain, Yousef A. Bin Jardan, Samir Ibenmoussa, Youssouf Ali Younous

    The study evaluated the anti-hyperlipidemic effects of myrcenol and curzerene on a high fat diet induced hyperlipidemia rat model. Thirty male albino rats were fed on a high-fat diet for four months. The HFD-induced hyperperlipidemia rats were treated with rosuvastatin (10 mg/kg), curzerene (130 mg/kg) and myrcenol (100 mg/kg) for four weeks. Blood samples were collected for further analysis. Aorta and heart were harvested for histopathological evaluation. Hepatic lipase and HMG-CoA reductase were determined by ELISA. FST and Y-maze tests were performed to assess the stress level in hyperlipidemia rats. The phytochemical compounds (Curzerene and Myrcenol) and the standard drug (Rosuvastatin) resulted in decreased body weight as well as reduced levels of LDL, TG, TC, AST and ALT as compared to the diseased group. Additionally, the treated groups displayed improved HDL levels and less depressed behavior. The ELISA results revealed that the Curzerene and myrcenol had significantly increased the protein concentration of hepatic lipase than the diseased group whereas both compounds significantly lowered the HMG-CoA reductase concentrations compared to the diseased group. The findings suggested that myrcenol and curzerene had the potential to be therapeutic agents for managing hyperlipidemia and reducing the risk of heart-related conditions associated with high lipid levels.


  • Open Access

    Anti-arthritic, immunomodulatory, and inflammatory regulation by the benzimidazole derivative BMZ-AD: Insights from an FCA-induced rat model

    by Haseeb Ahmad, Irfan Anjum, Halima Usman, Aisha Mobashar, Arham Shabbir, Yousef A. Bin Jardan, Amira Metouekel, Musaab Dauelbait, Mohammed Bourhia

    Rheumatoid arthritis (RA) is an autoimmune disease causing joint inflammation, deformity, cartilage deterioration, and pain. Benzimidazole derivatives exhibit various pharmacological properties. This study evaluated the antiarthritic, immunomodulatory, and anti-inflammatory potential of a benzimidazole derivative 2-(2-(benzylthio)-1 H -benzo[ d ]imidazol-1-yl)- N ′-(4-nitrobenzylidiene) acetohydrazide (BMZ-AD) in a Freund’s complete adjuvant (FCA)-induced arthritic rat model. FCA was administered on day 0, and treatment with BMZ-AD (25 mg/kg, 50 mg/kg, and 75 mg/kg) and piroxicam (10 mg/kg) began on day 7 and continued up to 28 days. Rats were sacrificed on day 28. Arthritis was assessed using an arthritic scoring index, and paw edema was measured with a digital water plethysmometer. Biochemical and hematological parameters were analyzed, reverse transcription polymerase chain reaction measured the mRNA expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), and molecular docking evaluated BMZ-AD interactions with these proteins. Enzyme-linked immunosorbent assay determined prostaglandin E2 levels. BMZ-AD treatment reduced inflammation, pannus formation, and pro-inflammatory cytokines (TNF-α and IL-6) and decreased PGE2 levels, comparable to piroxicam. Blood profiles improved with significant reductions in white blood cells and platelets in treatment groups. BMZ-AD demonstrated antiarthritic, anti-inflammatory, and immunomodulatory properties, suggesting that it could be a potential drug for RA treatment with fewer side effects.


  • Open Access

    Mechanistic Evaluation of Antiarthritic Effects of Citronellol in CFA-Induced Arthritic Rats

    by Eshwa Dar, Aisha Mobashar, Arham Shabbir, Muhammad Naveed Mushtaq, Irfan Anjum, Abdel-Rhman Z. Gaafar, Hiba-Allah Nafidi, Mohammed Bourhia

    Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation, joint tissue damage, pain, and synovitis. It leads to deformity of joints, disability, and even premature death. Markers of inflammation are highly expressed in synovium fluid and serum of arthritic patients and play an important role in the pathophysiology of RA. These transcription factors promote the fabrication of type I interferons and inflammatory cytokines. In RA, degradation of synovial cartilage and bone results from stimulation of proinflammatory cytokines. Citronellol (Ct), a monoterpene alcohol, is found in citrus fruits and essential oils of many aromatic plants. It possesses numerous pharmacological properties such as antioxidant activity and potential antinociceptive and anti-inflammatory effects. Keeping in view the significant anti-inflammatory role of Ct, a trial of 28 days was conducted. Ct was administered orally at three different doses (25, 50, and 100) mg/kg in Freund's adjuvant-induced arthritic rats, and the results were compared with piroxicam, chosen as the standard drug. The antiarthritic activity of the compound was evaluated through measurements of arthritic scoring and plethysmometry before and after treatment. The blood biochemical and hematological parameters and histopathological analyses were performed. Additionally, qPCR was conducted to analyze the mRNA expression levels of TNF-α, IL-1β, NF-κB, MMP3, IL-6, and IL-4 in the blood. ELISA was performed to evaluate the levels of PGE2. The results demonstrated that Ct showed significant results at all doses, but the highest dose proved to be most significant in terms of decreasing arthritic scoring and paw edema, indicating the antiarthritic potential of Ct. Furthermore, the compound was found to downregulate all the proinflammatory cytokines (TNF-α, IL-1β, NF-κB, MMP3, and IL-6) and upregulate the anti-inflammatory cytokine (IL-4). The levels of PGE2 were also reduced which further supported the antiarthritic effects of Ct and validated it as a potential antiarthritic candidate.


  • Open Access

    Amelioration of Rheumatoid Arthritis by Fragaria nubicola (Wild Strawberry) via Attenuation of Inflammatory Mediators in Sprague Dawley Rats

    by Kiran Mashaal, Arham Shabbir, Muhammad Shahzad, Aisha Mobashar, Tasleem Akhtar, Tabinda Fatima, Bushra Riaz, Rana Alharbi, Afreen Fatima, Abdulkareem A. Alanezi, et al.

    Background and Objectives: Fragaria nubicola has never been evaluated scientifically for its anti-arthritic potential despite its use in folkloric systems of medicine. The research was conducted to assess the potential of F. nubicola against rheumatoid arthritis. Materials and Methods: The current study provided scientific evidence by evaluating the effects of plants using an in vivo CFA-induced model of arthritic rats and subsequent microscopic histopathological evaluation of ankle joints along with the determination of paw edema using a digital water displacement plethysmometer. The study also gave insight by determining levels of pro-inflammatory cytokines, matrix metalloproteinase enzymes (MMPs), prostaglandin E2 (PGE2), nuclear factor kappa B (NF-κB), vascular endothelial growth factor (VEGF), and biochemical and hematological parameters. GCMS analysis was also conducted for the identification of possible anti-inflammatory plant constituents. Results: The data showed that F. nubicola-treated groups attenuated the progression of arthritis and paw edema. Microscopic histopathological evaluation validated the anti-arthritic potential by showing amelioration of bone erosion, infiltration of inflammatory cells, and pannus formation. RT-PCR analysis displayed that treatment with F. nubicola down-regulated IL1β, IL6, TNFα, NF-κB, VEGF, MMP2, MMP3, and MMP9 levels. Moreover, ELISA exhibited a reduction in levels of PGE2 levels in treatment groups. The levels of RBCs, platelets, WBCs, and Hb content were found to be nearly similar to negative control in the treated group. Statistically, a non-significant difference was found when all groups were compared for urea, creatinine, ALT, and AST analysis, indicating the safety of plant extract and fractions at test doses. GCMS analysis of extract and fractions showed the existence of many anti-inflammatory and antioxidant phytochemicals. Conclusion: In conclusion, F. nubicola possessed anti-arthritic properties that might be attributed to the amelioration of MMPs and pro-inflammatory cytokines.


  • Open Access

    Anti-Arthritic and Immunomodulatory Potential of Methanolic, n-Hexane, and Ethyl Acetate Fractions of Bark of Acacia modesta on Complete Freund’s Adjuvant-Induced Arthritis in Rats

    by Kiran Mashaal, Arham Shabbir, Mahtab Ahmad Khan, Huma Hameed, Muhammad Shahzad, Ali Irfan, Gamal A. Shazly, Aisha Mobashar, Tasleem Akhtar, Zaib Ali Shaheryar, et al.

    Rheumatoid arthritis is an autoimmune disorder and topic of interest for researchers due to its increasing frequency and limited treatment. Acacia modesta Wall is known to treat rheumatic disorders in the traditional system of medicinal plants. Traditional medicines are still required for the treatment of this disease due to the large number of side-effects caused by commercial medicines. In the current study, the antiarthritic potential of methanolic extract (AM-metha), n-hexane (AM-hexa) fraction, and ethyl acetate (AM-etha) fraction of the bark of A. modesta against a complete Freund’s adjuvant rat model was evaluated. Evaluation using a digital plethysmometer, macroscopic evaluation, and histopathological evaluation were conducted to determine the paw volume and arthritic scoring. ELISA was performed to assess the PGE2 levels. RT-PCR was used to evaluate the expression levels of MMP2, MMP3, MMP9, NF-κB, IL6, IL1β, TNFα, and VEGF. Biochemical and hematological analyses were also conducted. GC/MS was also carried out to analyze the presence of medicinal compounds. The data revealed a marked reduction in the paw volume, arthritic scoring, and histopathological parameters, indicating the anti-arthritic potential of the plant. Treatment with plant extracts and fractions markedly down-regulated MMP2, MMP3, MMP9, NF-κB, IL6, IL1β, TNFα, and VEGF levels. Similarly, PGE2 levels were also found to be ameliorated in the treatment groups, indicating the immunomodulatory property of plant bark. Plant treatment nearly normalized hematological parameters such as counts of WBCs, RBCs, and platelets, along with Hb content, thereby validating the anti-arthritic activity. GC/MS analysis disclosed the presence of strong anti-inflammatory compounds such as lupeol, oleic acid, and squalene. The study showed that A. modesta possesses anti-arthritic and immunomodulatory potential linked to significant down-regulation of pro-inflammatory and inflammatory biomarkers.